This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human PlGF Protein
catalog :
264-PGB
quantity :
10 ug (also 50 ug)
price :
299 USD
citations: 28
Reference |
---|
Hookham M, Ali I, O Neill C, Hackett E, Lambe M, Schmidt T, et al. Hypoxia-induced responses by endothelial colony-forming cells are modulated by placental growth factor. Stem Cell Res Ther. 2016;7:173 pubmed
|
Zhang Z, Ramirez N, Yankeelov T, Li Z, Ford L, Qi Y, et al. alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. Blood. 2008;111:1980-8 pubmed
|
Lin Y, Liang Y, Chiang B. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J Leukoc Biol. 2007;82:1473-80 pubmed
|
Mohamedali K, Poblenz A, Sikes C, Navone N, Thorpe P, Darnay B, et al. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 2006;66:10919-28 pubmed
|
Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal P, Pesce M, et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol. 2006;169:1167-82 pubmed
|
Moreno M, Ball M, Andrade M, McDermid A, Stanimirovic D. Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Glia. 2006;53:845-57 pubmed
|
Nozaki M, Sakurai E, Raisler B, Baffi J, Witta J, Ogura Y, et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest. 2006;116:422-9 pubmed
|
Niida S, Kondo T, Hiratsuka S, Hayashi S, Amizuka N, Noda T, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A. 2005;102:14016-21 pubmed
|
Sun J, Phung T, Shiojima I, Felske T, Upalakalin J, Feng D, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A. 2005;102:128-33 pubmed
|
Dikov M, Ohm J, Ray N, Tchekneva E, Burlison J, Moghanaki D, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2005;174:215-22 pubmed
|
Tamarat R, Silvestre J, Le Ricousse Roussanne S, Barateau V, Lecomte Raclet L, Clergue M, et al. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol. 2004;164:457-66 pubmed
|
Maynard S, Min J, Merchan J, Lim K, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-58 pubmed
|
Oura H, Bertoncini J, Velasco P, Brown L, Carmeliet P, Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood. 2003;101:560-7 pubmed
|
product information
brand :
R&D Systems
master code :
264-PGB
SKU :
264-PGB-010
product name :
Recombinant Human PlGF Protein
description :
The Recombinant Human PlGF Protein from R&D Systems is derived from E. coli. The Recombinant Human PlGF Protein has been validated for the following applications: Bioactivity.
target :
PlGF
category :
Proteins and Enzymes
unit size :
10 ug (also 50 ug)
buffer :
Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
conjugate :
Unconjugated
main entrez gene id :
5228
purity :
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Human
observed molecular weight :
12-15 kDa, reducing conditions
theoretical molecular weight :
15 kDa
gene symbol :
PGF
details of functionality :
Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF R1/Flt-1 Fc Chimera (Catalog # 3516-FL ) is immobilized at 0.5 µg/mL, 100 µL/well, the concentration of Recombinant Human PlGF that produces 50% of the optimal binding response is approximately 0.15-0.9 ng/mL.
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
catalog number base :
264-PGB
accessionNumbers :
P49763-2
applications :
Bioactivity
source :
The Recombinant Human PlGF Protein from R&D Systems is derived from E. coli. The Recombinant Human PlGF Protein has been validated for the following applications: Bioactivity.
USD :
299 USD
alt names :
D12S1900, PGF, PGFL, placenta growth factor, placental growth factor, placental growth factor, vascular endothelial growth factor-related protein, PlGF, PlGF-2, PLGFplacental growth factor-like, SHGC-10760
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
questions and comments